Agenda: Eliminating Bottlenecks to Advance CDx Commercialization & Adoption of New Therapies

6:00 pm Registration & Welcome Reception

6:30 pm Opening Remarks & Introduction

6:35 pm Panel Discussion & Q&A

  • Edwin Diaz Executive Director, Companion Diagnostics, Quest Diagnostics
  • Kristina McGuire Executive Director & Head, Precision Medicine Laboratory Operations & Companion Diagnostics, Regeneron Pharmaceuticals
  • Masayuki Kanai Senior Director, Global Companion Diagnostics Portfolio Leader, Daiichi Sankyo
  • Vijay Walia Senior Director, Companion Diagnostics, Quest Diagnostics
  • Yuri Fesko Executive Director, Medical Affairs, Quest Diagnostics
  • Matthew Silver Head, Oncology & Cell Therapy Companion Diagnostics, Takeda Pharmaceutical

Synopsis

Eliminating Bottlenecks to Advance CDx Commercialization & Adoption of New Therapies

  • Review the key challenges and strategies related to implementing CDx on a commercial scale
  • Hear from biopharma key leaders and CDx providers to gain insights on how to smoothly and effectively transition from trials to a   commercial environment
  • Discover how trial design can support the acceleration of reproducible results upon CDx therapy pairing

7:15 pm Networking & Drinks

Synopsis

This is an informal and exclusive networking opportunity for you to engage with biopharma leaders and Quest Diagnostics to discuss how to advance CDx commercialization.

8:00 pm Closing remarks & End of Quest Diagnostics Engager